Ryvu Therapeutics SA (RVU) — Cash Flow Reinvestment Rate

Latest as of December 2022: 3.31x

Ryvu Therapeutics SA (RVU) has a Cash Flow Reinvestment Rate of 3.31x as of December 2022, reinvesting zł198.08 Million (capex zł4.22 Million plus investments zł-193.87 Million) from operating cash flow of zł59.92 Million. See RVU FCF generation index to measure how efficiently the company converts operating cash flow to free cash.

Reinvestment Rate

3.31x
(Capex + Investments) / Operating CF

Total Reinvested

zł198.08 Million
Capex + Investments

Operating Cash Flow

zł59.92 Million
PLN

Capital Expenditures

zł4.22 Million
PLN

Ryvu Therapeutics SA Cash Flow Reinvestment Rate (2017–2022)

Historical reinvestment intensity for Ryvu Therapeutics SA across 2 annual periods. For the full cash flow conversion analysis, see RVU cash flow metrics.

Annual Cash Flow Reinvestment Rate for Ryvu Therapeutics SA (2017–2022)

Year-by-year capital reinvestment analysis for Ryvu Therapeutics SA. See RVU free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.

Year Reinvestment Rate Total Reinvested (PLN) Operating CF Capex YoY Change
2022 0.47x zł9.98 Million zł21.32 Million zł9.29 Million ▼ -85.8%
2017 3.30x zł36.26 Million zł10.98 Million zł21.56 Million
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow